FDA keeps Mounjaro off shortage list after reevaluation

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from federal drug shortage list amid intense pushback from compounded drug manufacturers. The FDA determined in October that the active ingredient in Mounjaro and Zepbound — tirzepatide — was...